WWL0245
Product Specifications
UNSPSC Description
WWL0245 is a potent and seletive BRD4 PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC50 (DC50>1 μM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4[1].
Target Antigen
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wwl0245.html
Solubility
10 mM in DMSO
Smiles
CC[C@@H](N(C1=N2)CC3CCCCC3)C4=NN=C(C)N4C1=CN=C2NC5=C(C=C(C=C5)C(NC6CCN(CC6)C(COC7=C8C(C(N(C9C(NC(CC9)=O)=O)C8=O)=O)=CC=C7)=O)=O)OC
Molecular Weight
873.96
References & Citations
[1]Rong Hu, et al. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. Eur J Med Chem. 2022 Jan 5;227:113922.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153519/WWL0245-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153519/
Clinical Information
No Development Reported
CAS Number
2869057-11-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items